Vanda Pharmaceuticals Q3 Loss Narrows to $22.6 Million as Revenue Jumps 24.1%

Vanda Pharmaceuticals (VNDA) reported a third-quarter net loss of $22.562 million, or $0.37 per share, compared with a loss of $22.586 million, or $0.38 per share, a year earlier, the company announced. Revenue for the period rose 24.1% to $69.815 million from $56.258 million last year. The company also issued full-year revenue guidance of $240 million.